Maryland Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $10.3M | Sell |
236,092
-47
| -0% | -$2.28K | 0.86% | 40 |
|
|
2022
Q2 | $12.4M | Buy |
236,139
+4,430
| +2% | +$226K | 0.97% | 37 |
|
|
2022
Q1 | $12M | Buy |
231,709
+25,570
| +12% | +$1.33M | 0.75% | 41 |
|
|
2021
Q4 | $12.2M | Buy |
206,139
+944
| +0.5% | +$46.8K | 0.66% | 37 |
|
|
2021
Q3 | $8.82M | Sell |
205,195
-11,623
| -5% | -$515K | 0.53% | 46 |
|
|
2021
Q2 | $8.49M | Buy |
216,818
+6,613
| +3% | +$257K | 0.51% | 47 |
|
|
2021
Q1 | $7.62M | Sell |
210,205
-9,803
| -4% | -$348K | 0.51% | 50 |
|
|
2020
Q4 | $8.1M | Buy |
220,008
+4,370
| +2% | +$160K | 0.57% | 43 |
|
|
2020
Q3 | $7.51M | Buy |
215,638
+8,670
| +4% | +$304K | 0.61% | 40 |
|
|
2020
Q2 | $6.42M | Buy |
206,968
+15,994
| +8% | +$543K | 0.59% | 44 |
|
|
2020
Q1 | $5.91M | Buy |
190,974
+27,827
| +17% | +$948K | 0.7% | 42 |
|
|
2019
Q4 | $6.06M | Buy |
163,147
+9,784
| +6% | +$348K | 0.64% | 43 |
|
|
2019
Q3 | $5.23M | Buy |
153,363
+7,085
| +5% | +$258K | 0.6% | 46 |
|
|
2019
Q2 | $6.01M | Buy |
146,278
+5,885
| +4% | +$234K | 0.71% | 40 |
|
|
2019
Q1 | $5.66M | Buy |
140,393
+16,314
| +13% | +$653K | 0.7% | 41 |
|
|
2018
Q4 | $5.14M | Buy |
124,079
+8,605
| +7% | +$357K | 0.74% | 37 |
|
|
2018
Q3 | $4.83M | Sell |
115,474
-2,495
| -2% | -$96K | 0.63% | 40 |
|
|
2018
Q2 | $4.06M | Buy |
117,969
+85
| +0.1% | +$2.9K | 0.57% | 45 |
|
|
2018
Q1 | $3.97M | Sell |
117,884
-3,269
| -3% | -$112K | 0.57% | 44 |
|
|
2017
Q4 | $4.16M | Sell |
121,153
-3,030
| -2% | -$103K | 0.62% | 42 |
|
|
2017
Q3 | $4.21M | Sell |
124,183
-2,499
| -2% | -$80.3K | 0.65% | 43 |
|
|
2017
Q2 | $4.04M | Buy |
126,682
+4,158
| +3% | +$131K | 0.58% | 43 |
|
|
2017
Q1 | $3.98M | Sell |
122,524
-3,102
| -2% | -$97.8K | 0.6% | 41 |
|
|
2016
Q4 | $3.87M | Buy |
125,626
+15,852
| +14% | +$484K | 0.6% | 44 |
|
|
2016
Q3 | $3.53M | Buy |
109,774
+3,908
| +4% | +$131K | 0.53% | 44 |
|
|
2016
Q2 | $3.54M | Buy |
105,866
+7,489
| +8% | +$239K | 0.56% | 43 |
|
|
2016
Q1 | $2.77M | Buy |
98,377
+13,229
| +16% | +$378K | 0.4% | 46 |
|
|
2015
Q4 | $2.61M | Buy |
85,148
+3,614
| +4% | +$114K | 0.38% | 49 |
|
|
2015
Q3 | $2.43M | Sell |
81,534
-14,659
| -15% | -$470K | 0.41% | 46 |
|
|
2015
Q2 | $3.06M | Buy |
96,193
+1,726
| +2% | +$56.3K | 0.48% | 43 |
|
|
2015
Q1 | $3.12M | Buy |
94,467
+3,109
| +3% | +$98.8K | 0.49% | 41 |
|
|
2014
Q4 | $2.7M | Buy |
91,358
+9,186
| +11% | +$263K | 0.44% | 47 |
|
|
2014
Q3 | $2.31M | Buy |
82,172
+12,529
| +18% | +$352K | 0.4% | 54 |
|
|
2014
Q2 | $1.96M | Buy |
69,643
+5,846
| +9% | +$167K | 0.34% | 58 |
|
|
2014
Q1 | $1.95M | Sell |
63,797
-40,772
| -39% | -$1.22M | 0.36% | 57 |
|
|
2013
Q4 | $3.04M | Sell |
104,569
-3,949
| -4% | -$115K | 0.48% | 45 |
|
|
2013
Q3 | $2.96M | Buy |
108,518
+2,696
| +3% | +$73.4K | 0.48% | 50 |
|
|
2013
Q2 | $2.81M | Buy |
+105,822
| New | +$2.92M | 0.49% | 47 |
|
Other funds holding PFE
Maryland Capital Management's PFE Position: Q3 2022 in Review
Maryland Capital Management reduced its Pfizer (PFE) stake by 0.02% in Q3 2022, selling an estimated $2.28K and leaving 236,092 shares worth $10.3M. The position accounts for 0.86% of the portfolio, ranked #40.
Maryland Capital Management first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $12.4M in Q2 2022. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- Maryland Capital Management held 236,092 shares of Pfizer worth $10.3M as of Q3 2022.
- Maryland Capital Management sold 47 Pfizer shares in Q3 2022, an estimated $2.28K.
- Pfizer made up 0.86% of Maryland Capital Management's portfolio in Q3 2022, its #40 holding.
- Maryland Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- Maryland Capital Management's Pfizer position peaked at $12.4M in Q2 2022.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on Maryland Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.